SCHEMBL12424707

SCHEMBL12424707

COc1ccc2c3c(c4c(c2c1)OC(c1ccccc1)(c1ccc(N2CCOCC2)cc1)C=C4)C1(CC(C)(C)CC(C)(C)C1)c1ccccc1-c1ccccc1-3

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.33
TSHR P16473 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPK1 P28482 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
POLB P06746 1/20 0.33
STK10 O94804 1/20 0.32
SLK Q9H2G2 1/20 0.32
ADAM17 P78536 1/20 0.31
ALDH1A1 P00352 4/20 0.31
KDM4E B2RXH2 3/20 0.31
TP53 P04637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
HTT P42858 2/20 0.31
ATM Q13315 2/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
PIK3CA P42336 1/20 0.30
PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20369879 0.97 MAPT (0.34) MAPTTSHRHSD17B10MAPK1KMT2A
SCHEMBL676103 0.97 MAPT (0.34) MAPTTSHRHSD17B10MAPK1KMT2A
SCHEMBL10102396 0.95 MAPT (0.33) MAPTTSHRHSD17B10MAPK1KMT2A
SCHEMBL10106918 0.94 MAPT (0.34) MAPTTSHRHSD17B10MAPK1KMT2A
SCHEMBL12424708 0.91 STK10 (0.34) MAPTKMT2ASMN1; SMN2STK10SLK
SCHEMBL10102279 0.91 MAPT (0.32) MAPTTSHRHSD17B10KMT2AALDH1A1
SCHEMBL12205490 0.90 KDM4E (0.32) MAPTSTK10SLKALDH1A1KDM4E
SCHEMBL13868746 0.90 RAB9A (0.33) MAPTKMT2ASTK10SLKADAM17
SCHEMBL10102281 0.89 MAPT (0.31) MAPTTSHRHSD17B10KMT2AALDH1A1
SCHEMBL13868656 0.89 PRKDC (0.36) MAPTTSHRHSD17B10MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7976739-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2011-07-12 US disclosed
US-7976739-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2011-07-12 US disclosed
EP-2055698-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2011-04-27 EP disclosed
US-20100230649-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed
US-20100230649-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100230649-A1 CHROMENE COMPOUND CCNT1, RB1, H1-0 MAPT 1352/4885TSHR 222/4885HSD17B10 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.